Karyopharm Therapeutics Inc. Stock price
Equities
KPTI
US48576U1060
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.495 USD | +1.01% | +3.52% | +69.94% |
Financials (USD)
Sales 2024 * | 147M | Sales 2025 * | 165M | Capitalization | 170M |
---|---|---|---|---|---|
Net income 2024 * | -146M | Net income 2025 * | -182M | EV / Sales 2024 * | 1.67 x |
Net Debt 2024 * | 74M | Net cash position 2025 * | - | EV / Sales 2025 * | 1.03 x |
P/E ratio 2024 * |
-1.21
x | P/E ratio 2025 * |
-1.41
x | Employees | 325 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.94% |
Latest transcript on Karyopharm Therapeutics Inc.
1 day | +0.34% | ||
1 week | +3.52% | ||
Current month | +26.72% | ||
1 month | +10.53% | ||
3 months | +59.21% | ||
6 months | +7.30% | ||
Current year | +69.94% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Paulson
CEO | Chief Executive Officer | 56 | 20-02-25 |
Mike Mason
DFI | Director of Finance/CFO | 49 | 19-02-24 |
Amama Sadiq
CTO | Chief Tech/Sci/R&D Officer | - | 23-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Garen Bohlin
BRD | Director/Board Member | 76 | 13-10-02 |
Barry Greene
BRD | Director/Board Member | 60 | 12-12-31 |
Director/Board Member | 59 | 13-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 1.49 | +0.67% | 51 957 |
24-03-27 | 1.48 | +6.47% | 1,301,235 |
24-03-26 | 1.39 | 0.00% | 543,984 |
24-03-25 | 1.39 | 0.00% | 581,779 |
24-03-22 | 1.39 | -2.11% | 792,757 |
Delayed Quote Nasdaq, March 28, 2024 at 09:41 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+69.94% | 170M | |
+2.38% | 108B | |
+10.11% | 104B | |
+6.61% | 23.66B | |
-11.92% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-13.33% | 16.19B | |
+3.61% | 13.72B | |
+34.71% | 12.22B |